Government's Women's Health Strategy Won't End Medical Misogyny – But Markets Could
Health Secretary Wes Streeting announced the government's renewed Women's Health Strategy this week, acknowledging that the NHS "too often gaslights women, treating their pain as an inconvenience." While this policy represents genuine progress, it alone cannot close the persistent health gap affecting women across the United Kingdom. The real transformation, argues capital allocator Maryann Selfe, will come from how financial markets respond to these policy signals.
The Strategy's Core Components
The government's approach includes several significant measures designed to address systemic issues in women's healthcare. A £1.5 million femtech challenge fund represents the headline innovation investment, though this amount must be viewed in context: women's health currently receives only about five percent of global research and development funding despite representing half the population and shouldering a disproportionate disease burden.
The strategy commits to reducing gynaecology waiting lists that currently affect more than 565,000 women, aiming to return to the NHS 18-week treatment standard. It integrates menopause care into routine NHS health checks and mandates that publicly funded research account for sex-based biological differences to qualify for funding. This last requirement proves particularly significant, as it systematically builds data infrastructure in a category that has historically lacked robust information systems.
From Niche Wellness to Core Healthcare Market
For decades, women's health has been framed as a wellness story – niche, values-led, and subscale. This perception has kept institutional capital largely on the sidelines. The 2026 strategy makes clear that women's health constitutes a core healthcare market that has been structurally undercapitalized. Markets lacking comprehensive data tend to be mispriced, and this mispricing is now beginning to correct across both US and European markets.
Recent acquisitions in women's oncology and reproductive health infrastructure are no longer isolated events but are forming recognizable patterns. Large strategic investors are recalibrating their approaches toward a category they have historically underweighted. The businesses being acquired increasingly represent platform assets with clearer commercial pathways, indicating a materially different exit environment compared to just five years ago.
Creating Conditions for Private Capital
If maintained, the government's strategy accelerates conditions for private capital deployment with greater confidence. Regulatory pathways become more predictable, reimbursement frameworks begin to shift, and NHS infrastructure built around women's health hubs creates procurement pipelines that previously didn't exist at scale. The National Institute for Health Research accelerator for female founders strengthens both talent and intellectual property pipelines.
All these developments help de-risk private investment in a sector that has been chronically underfunded. This strategy should be read not merely as a healthcare story but as a market structure narrative – the kind of policy signal that can precede a significant re-rating of an entire investment category.
The Investment Opportunity
For investors, the message is straightforward: a category that has been structurally underfunded for decades is now receiving explicit government mandate, data reform, and procurement commitment simultaneously. This combination rarely appears in healthcare markets. While government action alone cannot close the women's health gap, it clearly indicates the direction capital needs to move to complete the transformation.
The women's health market represents one of the most significant investment opportunities of our time, with the potential to deliver both financial returns and substantial social impact. As data infrastructure improves and regulatory frameworks evolve, private capital stands ready to scale innovations that public funding initiates, creating a powerful partnership between policy and markets.
